Cysteamine in the treatment of fibrotic disease
AssigneeSeattle Children's Research Institute
InventorsAllison A. Eddy, Daryl M. Okamura
Life of this patent
Estimating the term…
Abstract
Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ECM) deposition, interstitial fibroblasts, interstitial volume, expression of Collagen I mRNA and protein, expression of profibrotic cytokines and macrophage infiltration by Cysteamine treatment.
Claims23
A method of treating a fibrotic disease comprising administering, to a patient in need thereof, an effective amount of cysteamine, or a salt thereof;
- wherein the administration of cysteamine, or a salt thereof, results in amelioration of a fibrotic disease in the patient.
2-22. (canceled)
A method for treating a disorder associated with elevated levels of interstitial extracellular matrix (ECM) in a tissue, said method comprising administering, to a patient diagnosed with the disorder, an effective amount of cysteamine, or a salt thereof;
- wherein the administration of cysteamine, or a salt thereof, results in reduction or maintenance of the level of interstitial ECM in the tissue of the patient.
A method for reducing the progression of chronic kidney disease (CKD), said method comprising administering, to a patient diagnosed with CKD, an effective amount of cysteamine, or a salt thereof;
- wherein the administration of cysteamine, or a salt thereof, results in reducing CKD progression in the patient.
A method of ameliorating fibrosis in a patient, comprising:
- identifying a patient with fibrosis;
- and
- providing to said patient cysteamine, or a salt thereof, wherein an amelioration of fibrosis in said patient is observed.
Dependencies are inferred from the claim text.